



A Leader in Pharmaceutical, Biotechnology and Medical Device R&D Outsourcing

Transforming Drug Discovery

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.

WuXi's global operations provide services to more than 80 pharmaceutical and biotechnology customers including 9 of the top 10 pharmaceutical companies. The company employs nearly 3,300 people in China and the U.S. WuXi PharmaTech launched its IPO of American Depository Shares (ADSs) on the NYSE in August 2007 and trades under the ticker symbol "WX".

Investment Profile

Market cap	\$1.31 B
Current price	\$21.02
52 wk high	\$45.65
52 wk low	\$14.00
ADS outstanding	62.45 M

Price as of July 15, 2008
Source: NYSE, Bloomberg

Continuing to Build Positive Momentum in 2008

1Q08 results compared to 1Q07:

Revenue **♦ 69%**

Net income **♦ 132%**


Gross profit **♦ 55%**

Laboratory Services revenue **♦ 77%**

Research Manufacturing revenue **♦ 53%**

Results include AppTec performance in 2 month post-acquisition period following deal close on January 31, 2008

Integrated Full Life Cycle R&D Services



With High Customer Retention

80 customers in 2007

Clients include 9 of the world's top 10 pharmaceutical companies by revenue

100% repeat business from top 10 customers over last 3 years

WX stand-alone

Competitive Edge in R&D Outsourcing


Leadership	- Experienced management team with international business practices
Workforce	- Over 45% of employees hold Masters and PhD degrees
Infrastructure	- World class R&D equipment and global facilities
Customers	- Diversified customer base of industry leading players
Trust	- Intellectual property protection procedures ensure customer confidentiality





A Leader in Pharmaceutical, Biotechnology and Medical Device R&D Outsourcing

Consistent Track Record of Profitable Growth



¹ Excluding share-based compensation charges of approximately US\$0 in 2004, US\$3.1 million in 2005, US\$8.1 million in 2006, and US\$0.3 million in 1Q 2006 and US\$3.4 million in 1Q 2007

First Quarter 2008 Operational Milestones

- ▶ Suzhou GLP Center and Jinshan expansion on schedule
- ▶ Completed global sales force training
- ▶ Integrating financial reporting system between China and the US
- ▶ Successfully implemented ERP system in Shanghai and Tianjin
- ▶ Establishing direct IT links between US and China operations



Growth Strategy: Expanding Services, Longer and Larger Customer Contracts

Core Laboratory Services Capacities Growth	-	Increased recruitment and staff retention at Tianjin R&D campus will allow for more service capacity for customers
Expansion of Research Manufacturing Capability and Capacity	-	Extension of Jinshan center will facilitate larger scale and repeated research manufacturing projects
Development of Significant Preclinical and Biology Capabilities	-	Establishment of the JV with Covance for larger Suzhou Nonclinical Toxicology GLP Center will expand portfolio of services offered to customers

Becoming the Global R&D Outsourcing Leader: Major Strategic Initiatives

- ▶ In January 2008, WuXi PharmaTech acquired AppTec Laboratory Services for approximately \$151 million with the assumption of \$11.7 million in debt. The transaction was immediately accretive to pro forma earnings¹.

- ▶ In June 2008, WuXi PharmaTech and Covance decided to create a 50-50 joint venture to provide GLP toxicology, drug metabolism and bioanalytical chemistry services in Suzhou, China.

¹ Excludes any acquisition related amortization and one-time transaction costs

Contact Details

Dr. Hai Mi
VP, Corporate Communications
WuXi PharmaTech Co., Ltd
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai, PRC 200131
+86-21-5046-3726
ir@pharmatechs.com

Mahmoud Siddig
Director
Taylor Rafferty
205 Lexington Avenue
8th Floor
New York, NY 10007
+1-212-889-4350
pharmatechs@taylor-rafferty.com

Ruby Yim
Managing Director
Taylor Rafferty
Room 3213, Cosco Tower
183 Queen's Road Central
Hong Kong, China
+852-3196-3712
pharmatechs@taylor-rafferty.com

Analyst Coverage

BNP Paribas
Citigroup
Credit Suisse
Evolution Securities China
Global Hunters Securities
HSBC Research
Jefferies & Co.
JP Morgan
Natixis Bleichroeder
Oppenheimer & Co.
Strategic Int'l Securities
UBS